Analysis of Clinical Application of China's First Batch of TYRX Absorbable Antibacterial Envelope

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06710873

Enrollment

Registered

2024-11-29

Start date

2023-12-01

Completion date

2026-03-01

Last updated

2025-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CIED Infection, TYRX Absorbable Antibacterial Envelope

Brief summary

This study is the first to use TYRX domesticly, reporting and summarizing its usage to validate its real-world effectiveness in CIED infection prevention.

Detailed description

This study is the first to use TYRX domesticly, reporting and summarizing its usage to validate its real-world effectiveness in CIED infection prevention.

Interventions

DEVICETYRX Absorbable Antibacterial Envelope

All enrolled patients will receive the TYRX Absorbable Antibacterial Envelope implanted simultaneously during the CIED surgery.

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* All patients who received the TYRX absorbable antimicrobial envelopes at our hospital from December 2023 to September 2024

Exclusion criteria

* Allergies to the envelope materials or antimicrobial drugs (minocycline and other tetracyclines, rifampin) * Existing infections at the CIED implantation site * Pregnant or breastfeeding women * children and adolescents

Design outcomes

Primary

Measure	Time frame	Description
CIED infection	three months post-surgery	The infection rate related to CIEDs at three months post-surgery

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026